The present invention relates to a stable antibody-containing liquid preparation which rarely undergoes the formation of aggregates of Emicizumab (ACE910) that is a bispecific antibody having a function alternative to the function of FVIII. More specifically, the present invention relates to the aforementioned antibody-containing liquid preparation which contains 20 to 180 mg/mL of the aforementioned bispecific antibody, 10 to 40 mM of a histidine-aspartate buffer solution, 0.2 to 1 mg/mL of Poloxamer 188 and 100 to 300 mM of arginine and has a pH value of 4.5 to 6.5.本發明係有關於取代FVIII功能之雙重專一性抗體Emicizumab(ACE910)之可抑制聚集體形成之含安定之抗體的溶液製劑,具體來說,係關於為含有20~180mg/mL上述雙重專一性抗體、10mM~40mM組胺酸-天門冬胺酸鹽緩衝液、0.2~1mg/mL Poloxamer 188及100mM~300mM精胺酸,pH值為4.5~6.5之上述含抗體溶液製劑。